Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALLO-316
- Development stage
- Unknown
- Lead developer
- Allogene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ALLO-316 is an engineered, off-the-shelf, allogeneic chimeric antigen receptor T (CAR-T) cell therapy targeting CD70 (CD70 antigen). It is being developed as part of Allogene Therapeutics' AlloCAR T™ platform for the treatment of solid tumors, particularly renal cell carcinoma (RCC). The therapy has the TCRα constant gene knocked out to reduce the risk of graft-vs-host disease and the CD52 gene knocked out to permit the use of ALLO-647, an anti-CD52 antibody, for lymphodepletion without affecting the CAR-T cells. The CAR is designed to avoid fratricide and includes a CD20 mimotope-based intra-CAR off switch that allows the CAR-T cells to be eliminated with rituximab.
- Other names
- allogeneic anti-CD70-CAR T cells ALLO-316
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on ALLO-316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALLO-316.